Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma

• Published in: BMC clinical pathology Vol. 17; no. 1; p. 3
• Main Authors: El Ochi, Mohamed Reda, Oukabli, Mohamed, Bouaiti, Elarbi, Chahdi, Hafsa, Boudhas, Adil, Allaoui, Mohamed, Ameur, Ahmed, Abbar, Mohamed, Al Bouzidi, Abderrahmane
• Format: Journal Article
• Language: English
• Published: England BioMed Central 04-04-2017
• Subjects: Age; Bladder cancer; Breast cancer; Classification; Epidermal growth factor; Growth factor receptors; Hybridization; Medical prognosis; Multivariate analysis; Oncology; Protein expression; Proteins; Tumors; Urinary bladder; United States > US; Bladder; Carcinoma; HER2; Urothelial
• ISSN: 1472-6890; 1472-6890
• DOI: 10.1186/s12907-017-0046-z

Urothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters.
103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody.
HER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (
 = 0.003) and pathological stage (
 = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (
 = 0.04).
HER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior.